Literature DB >> 16509811

Aprotinin in cardiac surgery.

Neel R Sodha1, Munir Boodhwani, Cesario Bianchi, Basel Ramlawi, Frank W Sellke.   

Abstract

Aprotinin is a naturally occurring serine protease inhibitor that is being used with increasing frequency in cardiac surgery and beyond to reduce blood loss and the need for perioperative blood transfusion. Through inhibition of serine proteases such as plasmin, aprotinin significantly reduces fibrinolysis, thereby aiding hemostasis during surgical procedures. In addition, aprotinin interacts with other factors in the coagulation and fibrinolytic cascade, creating a hemostatic balance, without increasing the risk of thrombosis. These proven benefits are supplemented by the anti-inflammatory properties of aprotinin, which may help curb some of the deleterious effects of cardiopulmonary bypass. This article will review the discovery of aprotinin, its mechanism of action, dosing and adverse effects, and highlight the major recent trials demonstrating its efficacy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16509811     DOI: 10.1586/14779072.4.2.151

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  4 in total

1.  Clinical evaluation of leukocyte filtration as an alternative anti-inflammatory strategy to aprotinin in high-risk patients undergoing coronary revascularization.

Authors:  Bora Farsak; Serdar Gunaydin; Ulku Yildiz; Tamer Sari; Yaman Zorlutuna
Journal:  Surg Today       Date:  2011-11-10       Impact factor: 2.549

2.  Plasmin inhibitors prevent leukocyte accumulation and remodeling events in the postischemic microvasculature.

Authors:  Christoph A Reichel; Max Lerchenberger; Bernd Uhl; Markus Rehberg; Nina Berberich; Stefan Zahler; Matthias P Wymann; Fritz Krombach
Journal:  PLoS One       Date:  2011-02-22       Impact factor: 3.240

Review 3.  A benefit-risk review of systemic haemostatic agents: part 1: in major surgery.

Authors:  Ian S Fraser; Robert J Porte; Peter A Kouides; Andrea S Lukes
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  The effect of L-arginine and aprotinin on intestinal ischemia-reperfusion injury.

Authors:  Constantine P Spanos; Panagiota Papaconstantinou; Panagiotis Spanos; Michael Karamouzis; George Lekkas; Christos Papaconstantinou
Journal:  J Gastrointest Surg       Date:  2007-03       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.